These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1413197)

  • 1. [Consumption of psilocybin-containing hallucinogenic mushrooms by young people].
    Lassen JF; Lassen NF; Skov J
    Ugeskr Laeger; 1992 Sep; 154(39):2678-81. PubMed ID: 1413197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM; Dean A; Knecht ZA; Spencer J; Taverna EC
    Drug Alcohol Depend; 2013 Jun; 130(1-3):245-8. PubMed ID: 23265089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms].
    Lassen JF; Ravn HB; Lassen SF
    Ugeskr Laeger; 1990 Jan; 152(5):314-7. PubMed ID: 2301080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hallucinogenic mushroom use by Danish students: pattern of consumption.
    Lassen JF; Lassen NF; Skov J
    J Intern Med; 1993 Feb; 233(2):111-2. PubMed ID: 8433070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hallucinogenic psilocybine-containing mushrooms. Patterns of use among Danish abusers].
    Lassen JF; Lassen NF; Skov J
    Ugeskr Laeger; 1993 May; 155(18):1368-70. PubMed ID: 8497968
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hallucinogenic mushrooms in Denmark].
    Holm JW; Ebbehøj NE; Fjeldberg IA
    Ugeskr Laeger; 1997 Aug; 159(34):5116-8. PubMed ID: 9297322
    [No Abstract]   [Full Text] [Related]  

  • 7. [Automutilation after consumption of hallucinogenic mushrooms].
    Attema-de Jonge ME; Portier CB; Franssen EJ
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2869-72. PubMed ID: 18257429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hallucinogenic mushrooms.
    Schwartz RH; Smith DE
    Clin Pediatr (Phila); 1988 Feb; 27(2):70-3. PubMed ID: 3338231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hallucinogenic mushrooms].
    Reingardiene D; Vilcinskaite J; Lazauskas R
    Medicina (Kaunas); 2005; 41(12):1067-70. PubMed ID: 16401965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
    Licht CL; Christoffersen M; Okholm M; Damgaard L; Fink-Jensen A; Knudsen GM; Erritzoe D
    Hum Psychopharmacol; 2012 Jul; 27(4):352-63. PubMed ID: 22696164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin.
    Gambaro V; Roda G; Visconti GL; Arnoldi S; Casagni E; Dell'Acqua L; Farè F; Paladino E; Rusconi C; Arioli S; Mora D
    J Pharm Biomed Anal; 2016 Jun; 125():427-32. PubMed ID: 27021629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions.
    Beck O; Helander A; Karlson-Stiber C; Stephansson N
    J Anal Toxicol; 1998; 22(1):45-9. PubMed ID: 9491968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The danger of hallucinogenic mushrooms.
    Mills PR; Lesinskas D; Watkinson G
    Scott Med J; 1979 Oct; 24(4):316-7. PubMed ID: 555819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
    Roberts CA; Osborne-Miller I; Cole J; Gage SH; Christiansen P
    J Psychopharmacol; 2020 Sep; 34(9):999-1007. PubMed ID: 32674668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Between prohibitions: patterns and meanings of magic mushroom use in the UK.
    Riley SC; Blackman G
    Subst Use Misuse; 2008; 43(1):55-71. PubMed ID: 18189205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turn on, tune in, but don't drop out: The impact of neo-liberalism on magic mushroom users' (in)ability to imagine collectivist social worlds.
    Riley S; Thompson J; Griffin C
    Int J Drug Policy; 2010 Nov; 21(6):445-51. PubMed ID: 20810266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peculiar plants and fantastic fungi: An ethnobotanical study of the use of hallucinogenic plants and mushrooms in Slovenia.
    Fatur K
    PLoS One; 2021; 16(1):e0245022. PubMed ID: 33412556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR; Kaar S; Borschmann R
    J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.